Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.40 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132524 | 0.94 | TOP2A (0.43) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25132883 | 0.86 | TTR (0.45) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL23869696 | 0.84 | MAPT (0.38) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25969880 | 0.84 | MAPT (0.43) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25603214 | 0.83 | ALDH1A1 (0.43) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25129541 | 0.81 | TTR (0.45) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL23765661 | 0.79 | DHODH (0.32) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL22732889 | 0.77 | TOP2A (0.59) | TOP2AALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL14726017 | 0.77 | TDP1 (0.47) | ALDH1A1SMN1; SMN2MAPTKDM4EL3MBTL1 | |
| SCHEMBL25895953 | 0.76 | TDO2 (0.39) | ALDH1A1SMN1; SMN2MAPTKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | TOP2A 3525/4885ALDH1A1 3165/4885SMN1; SMN2 3952/4885 |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | TOP2A 217/4885ALDH1A1 2465/4885SMN1; SMN2 2346/4885 |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | CD2BP2, CD47, BCR | TOP2A 1569/4885ALDH1A1 3518/4885SMN1; SMN2 1767/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | TOP2A 2750/4885ALDH1A1 3285/4885SMN1; SMN2 2830/4885 |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | CD209, CD22, CD47 | TOP2A 2957/4885ALDH1A1 4615/4885SMN1; SMN2 3653/4885 |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1LG2, CD274, PDCD1 | TOP2A 368/4885ALDH1A1 3313/4885SMN1; SMN2 2679/4885 |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | TOP2A 1054/4885ALDH1A1 3816/4885SMN1; SMN2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.